Who is sponsoring NCT03569540?

NCT03569540 is sponsored by University of Sao Paulo General Hospital.

What drugs are being tested in NCT03569540?

Interventions in NCT03569540: Glibenclamide, Placebo.

What condition does NCT03569540 study?

NCT03569540 studies Subarachnoid Hemorrhage, Aneurysmal.

Is NCT03569540 still recruiting?

NCT03569540 is currently status unknown. Last updated 26 June 2018.

Last reviewed 2018-06-26 · How we verify

NCT03569540: GASH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage

Status unknown Phase 4 Last updated 26 June 2018

What this trial tests

Phase 4 trial testing Glibenclamide in Subarachnoid Hemorrhage, Aneurysmal in 50 participants. Status unknown.

Timeline

3 July 2018

Primary endpoint
1 July 2019

1 December 2019

Quick facts

Lead sponsor	University of Sao Paulo General Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	3 July 2018
Primary completion	1 July 2019
Estimated completion	1 December 2019
Sites	1 location across Brazil

Drugs / interventions tested

Glibenclamide (glibenclamide) — full drug profile →
Placebo

Conditions studied

Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →

Sponsor

University of Sao Paulo General Hospital

Who can join

Adults 18 to 70, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind and prospective trial meant to evaluate the use of Glibenclamide on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated randomly in two groups, one for 05 mg daily intake of glibenclamide for 21 days and another for control with placebo. General clinical data and late cognitive status will be accessed in both groups.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Sulfonylurea Receptor 1 in Central Nervous System Injury: An Updated Review.
Jha RM, Rani A, Desai SM, Raikwar S, et al · · 2021 · cited 35× · PMID 34769328 · DOI 10.3390/ijms222111899
Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial.
da Costa BBS, Windlin IC, Koterba E, Yamaki VN, et al · · 2019 · cited 14× · PMID 31288831 · DOI 10.1186/s13063-019-3517-y

Verify or expand the search:

Other trials of Glibenclamide

Trials testing the same drug.

NCT05687500 — Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) · Phase 2 · recruiting
NCT03284463 — Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism · Phase 2, PHASE3 · completed
NCT02375828 — Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels · Phase 3 · completed
NCT02318693 — Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Melli · Phase 4 · completed

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03569540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
Last refreshed: 26 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03569540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing